J.P. Morgan Maintains a Buy Rating on CeriBell (CBLL) With a $21 PT

CeriBell, Inc. (NASDAQ:CBLL) is one of the best medical device stocks to buy according to analysts. J.P. Morgan analyst Robbie Marcus maintained a Buy rating on CeriBell, Inc. (NASDAQ:CBLL) on August 5, setting a price target of $21.00.

The rating update came after CeriBell, Inc. (NASDAQ:CBLL) reported its Q2 results on the same day, with total revenue for the quarter reaching $21.2 million and reflecting a 38% growth compared to the same quarter last year.

CeriBell, Inc. (NASDAQ:CBLL) also attained a gross margin of 88% in Q2 2025, and ended the quarter with 584 total active accounts.

CeriBell, Inc. (NASDAQ:CBLL) is a commercial-stage medical technology company that engages in the diagnosis and management of patients with serious neurological conditions. The company’s products include Point-of-Care EEG, EEG Portal, and Clarity.

While we acknowledge the potential of CBLL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.